Search

Displaying results 5141 - 5150 of 10000 in total
  1. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    It is an experimental therapy that is being developed by NeoRx Corporation. … SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in

  2. Drug

    Octamoxin

    go.drugbank.com/drugs/DB09249
    ApprovedWithdrawn

    This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.

  3. Drug

    TG-100801

    go.drugbank.com/drugs/DB05075
    Investigational

    It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological … TG100801 is a topically applied kinase inhibitor in macular degeneration patients.

  4. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. … [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity

    Categories: Amino Acids, Peptides, and Proteins
  5. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this

  6. Drug

    Zaleplon

    go.drugbank.com/drugs/DB00962
    ApprovedIllicit

    Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States. … Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic.

    Categories: Hypnotics and Sedatives, Benzodiazepine hypnotics and sedativesSynonyms: 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
  7. Drug

    Fursultiamine

    go.drugbank.com/drugs/DB08966
    Approved

    It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.

  8. Drug

    Metixene

    go.drugbank.com/drugs/DB00340
    Approved

    Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.

  9. Drug

    REP8839

    go.drugbank.com/drugs/DB05224
    Experimental

    REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

  10. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.